Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01135524
Other study ID # BUP3019S
Secondary ID
Status Terminated
Phase Phase 3
First received June 1, 2010
Last updated September 5, 2012
Start date April 2004
Est. completion date August 2005

Study information

Verified date September 2012
Source Purdue Pharma LP
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this phase is to evaluate the long-term safety and tolerability of BTDS. Qualified subjects are started on BTDS 5 and the dose may be titrated, if necessary, to a maximum of BTDS 20 to achieve stable pain control.


Description:

Buprenorphine is a synthetic opioid analgesic with over 25 years of international clinical experience indicating it to be safe and effective in a variety of therapeutic situations for the relief of moderate to severe pain.


Recruitment information / eligibility

Status Terminated
Enrollment 196
Est. completion date August 2005
Est. primary completion date August 2005
Accepts healthy volunteers No
Gender Both
Age group 40 Years and older
Eligibility Inclusion Criteria:

- Subjects who completed all visits of the double-blind phase on study drug and subjects who discontinued study drug due to lack of therapeutic effect in the double-blind phase but completed all visits of the double-blind phase off study drug are eligible to enroll in the extension phase.

Exclusion Criteria:

- Subjects who prematurely discontinue study drug in the double-blind phase due to adverse event, subject's choice, administrative reason or lost to follow-up are NOT eligible to enter the extension phase

- Subjects with electrocardiograms (ECGs) that show any QT data corrected for heart rate using Fridericia formula (QTcF) interval = 500 millisecond (msec) will be discontinued from the extension phase.

- Subjects requiring long-acting opioid analgesics (once- or twice-daily dosing with an every (q) 24 hour (h) or q12h drug) or transdermal fentanyl during the extension phase should be discontinued from the study.

Refer to core study for additional inclusion/exclusion information.

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Buprenorphine transdermal patch
Buprenorphine transdermal patch 5 mcg/h applied transdermally for 7-day wear.
Buprenorphine transdermal patch
Buprenorphine transdermal patch 10 mcg/h applied transdermally for 7-day wear.
Buprenorphine transdermal patch
Buprenorphine transdermal patch 20 mcg/h applied transdermally for 7-day wear.

Locations

Country Name City State
United States Alabama Neurology and Pain Medicine Alabaster Alabama
United States Research Facility Altoona Pennsylvania
United States Allergy ARTS Amarillo Texas
United States Research Facility Baltimore Maryland
United States Crystal Lake Health Center Benzonia Michigan
United States Research Facility Birmingham Alabama
United States The Birmingham Pain Center Birmingham Alabama
United States University of Alabama Hospital Birmingham Alabama
United States Research Facility Boise Idaho
United States Research Facility Bridgeport Connecticut
United States Research Facility Brockton Massachusetts
United States Research Facility Buena Park California
United States The Arthritis Clinic and Carolina Bone and Joint Charlotte North Carolina
United States Research Facility Chicago Illinois
United States Research Facility Chula Vista California
United States Research Facility Cincinnati Ohio
United States Patuxent Medical Group Columbia Maryland
United States Research Facility Columbus Ohio
United States Research Facility Conroe Texas
United States Research Facility Coral Gables Florida
United States Family Practice Associates Corpus Christi Texas
United States New England Center for Clinical Research Cranston Rhode Island
United States Research Facility Dallas Texas
United States Research Facility Dallas Texas
United States Research Facility Daytona Beach Florida
United States Research Facility Duncansville Pennsylvania
United States Triangle Orthopaedic Associates Durham North Carolina
United States Research Facility Eugene Oregon
United States HealthSouth Metro West Hospital Fairfield Alabama
United States Research Facility Fresno California
United States Research Facility Greensboro North Carolina
United States Radiant Research Greer South Carolina
United States Research Facility Hagerstown Maryland
United States Research Facility Hialeah Florida
United States Research Facility Hickory North Carolina
United States Cornerstone Research Care High Point North Carolina
United States Hot Springs Pain Clinic Hot Springs Arkansas
United States Research Facility Houston Texas
United States KC Pain Centers East Independence Missouri
United States The Clinical Trial Center Jenkintown Pennsylvania
United States Research Facility Jupiter Florida
United States Rheumatology PC Kalamazoo Michigan
United States Research Facility Lansing Michigan
United States Research Facility Largo Florida
United States Research Facility Las Vegas Nevada
United States Research Facility Las Vegas Nevada
United States Research Facility Los Gatos California
United States Louisville Endocrinology PSC Louisville Kentucky
United States Research Facility Madisonville Kentucky
United States Research Facility Marietta Georgia
United States Research Facility Mechanicsburg Pennsylvania
United States Idaho Arthritis Osteoporosis Meridian Idaho
United States Research Facility Miami Florida
United States Research Facility Milwaukee Wisconsin
United States Research Facility New Berlin Wisconsin
United States Dolby Providers New Orleans Louisiana
United States Research Facility New Orleans Louisiana
United States Research Facility New Orleans Louisiana
United States Research Facility New York New York
United States Research Facility North Miami Beach Florida
United States Research Facility Ocala Florida
United States Research Facility Oklahoma City Oklahoma
United States Research Facility Ormond Beach Florida
United States Research Facility Palm Harbor Florida
United States Research Facility Pembroke Pines Florida
United States Arizona Research Center Phoenix Arizona
United States Research Facility Phoenix Arizona
United States Research Facility Phoenix Arizona
United States Radiant Research Pinellas Park Florida
United States Research Facility Plantation Florida
United States Research Facility Port Orange Florida
United States Research Facility Pueblo Colorado
United States KRK Medical Research Richardson Texas
United States Research Facility Roseville California
United States Research Facility San Antonio Texas
United States Research Facility San Antonio Texas
United States NTOUCH Research Corporation San Diego California
United States Research Facility San Diego California
United States Research Facility Spokane Washington
United States Research Facility Springfield Illinois
United States HealthCare Research LLC St. Louis Missouri
United States Research Facility St. Louis Missouri
United States Research Facility Syracuse New York
United States Research Facility Tampa Florida
United States Research Facility Torrence California
United States Research Facility Tucson Arizona
United States Research Facility Upland California
United States Integrated Clinical Trials West Des Moines Iowa
United States Research Facility West Palm Beach Florida

Sponsors (1)

Lead Sponsor Collaborator
Purdue Pharma LP

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The Number of Participants With Adverse Events as a Measure of Safety and Tolerability Safety was assessed using reports of adverse events, clinical laboratory results, findings from physical examinations, and vital sign measurements. 52 weeks Yes
See also
  Status Clinical Trial Phase
Completed NCT04657926 - A Trial of APPA in the Treatment of Knee Osteoarthritis Phase 2
Completed NCT02536833 - A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects Phase 2
Completed NCT03014037 - Comparing Mesenchymal Stem Cell Counts in Unilateral vs. Bilateral Posterior Superior Iliac Spine Bone Marrow Aspiration N/A
Recruiting NCT05937542 - A Qualitative Investigation of CLEAT Participants
Completed NCT03644615 - A Mindfulness Program (MBSR) in the Management of Symptomatic Hip and Knee Osteoarthritis N/A
Recruiting NCT06061367 - Muscles Strength and Gait Parameteres After TKA
Withdrawn NCT04976972 - A Comparison of Patients Receiving a Total Knee Replacement With Robotic Assistance or With Conventional Instrumentation N/A
Completed NCT05496205 - A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers Phase 1
Completed NCT03850665 - Comparison of Functional Outcome in Patients After Hip Arthroplasty Depending on Surgical Approach N/A
Completed NCT02826902 - Effect of Anesthesia on Quality of Recovery in Patients Undergoing Correctional Tibial Osteotomy - A Randomized Controlled Trial N/A
Completed NCT04402502 - Dynamic 4DCT to Examine Wrist Carpal Mechanics N/A
Completed NCT02923700 - Leukocyte-rich PRP vs Leukocyte-poor PRP for the Treatment of Knee Cartilage Degeneration: a Randomized Controlled Trial Phase 4
Completed NCT04564053 - Study of Safety, Tolerability and Pharmacokinetics of LNA043 in Japanese Osteoarthritis Participants Phase 1
Completed NCT05070871 - A Clinical Trial Investigating the Effect of Salmon Bone Meal on Osteoarthritis Among Men and Women N/A
Not yet recruiting NCT05036174 - Diphenhydramine Ointment for Knee Osteoarthritis N/A
Recruiting NCT02666443 - Low Dose Dexamethasone in Supraclavicular Blocks N/A
Recruiting NCT02912429 - Onlay vs. Inlay Patellofemoral Arthroplasty N/A
Active, not recruiting NCT02723929 - Effects of tDCS and tUS on Pain Perception in OA of the Knee
Withdrawn NCT02921594 - Kinematic Comparison of Vanguard XP and Vanguard CR Total Knee Arthroplasties N/A
Terminated NCT02820766 - Journey II BCS CMS Total Knee System Compared to Other PS Total Knee Systems in PT Setting N/A

External Links